pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·15h ago·1 min read
save

Stryker appoints Spencer Stiles as CEO, Kevin Lobo to become Executive Chair

Oct 7, 2026·read at Fierce Biotech ↗Neutral

Stryker announced a leadership change, naming Spencer Stiles as the new chief executive officer.

Stiles, who has been president and COO, will also join the board. Kevin Lobo, who has led the company since 2012, will shift to the role of executive chair of the board effective Jan. 1, 2027.

Lobo’s tenure saw the company’s net sales grow from $8.7 billion in 2012 to over $26 billion in 2026, expanding its portfolio and global reach. He praised Stiles’ leadership and the board’s succession planning.

source

This writeup was produced by pharmadog from original reporting by Fierce Biotech.

Original headline: “Stryker strikes up a new CEO in Spencer Stiles as Kevin Lobo moves upstairs”

read at Fierce Biotech ↗
441 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Medical Device Company3

related stories

  • Aug 4KKR inks $5.7B deal to take medtech manufacturing giant Integer privateFierce Biotech
  • Aug 3Curium strikes up to $8B deal for radiopharma rival LantheusFierce Biotech
  • Aug 3Fiercest Women in Life Sciences 2026: Nominations open nowFierce Biotech
  • Aug 3Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacityBioSpace
  • Jul 30Labcorp posts higher Q2 earnings on strength of diagnostics, lab services; adjusts full-year guidanceFierce Biotech